(Q31105792)

28 June 2017

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials (English)

1 reference

28 June 2017

phase III clinical trial

0 references

1 reference

1 reference

Kun-Ho Yoon

1

1 reference

28 June 2017

Rimei Nishimura

2

1 reference

28 June 2017

Jisoo Lee

3

1 reference

28 June 2017

Susanne Crowe

4

1 reference

28 June 2017

Afshin Salsali

5

1 reference

28 June 2017

Thomas Hach

6

1 reference

28 June 2017

Hans J Woerle

7

1 reference

28 June 2017

6 June 2016

1 reference

Diabetes, Obesity and Metabolism

28 June 2017

1 reference

28 June 2017

18

1 reference

28 June 2017

10

1 reference

28 June 2017

1045-1049

1 reference

Global estimates of diabetes prevalence for 2013 and projections for 2035.

28 June 2017

1 reference

Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

21 January 2018

1 reference

Comprehensive risk assessments of diabetic patients from seven Asian countries: The Joint Asia Diabetes Evaluation (JADE) program

21 January 2018

1 reference

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

21 January 2018

1 reference

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

21 January 2018

1 reference

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States

21 January 2018

1 reference

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12699

1 reference

28 June 2017

1 reference